Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > August 29, 2022
Daily News
August 29, 2022
- Japan Eyes FY2023 Launch of Pandemic Response Agency
August 29, 2022
- Tussle in Japan Diabetes Market Heating Up; BI and Sumitomo Nip and Tuck for No. 1 Slot
August 29, 2022
- Kymriah Now Approved for Follicular Lymphoma in Japan: Novartis
August 29, 2022
- MHLW’s Health Service Bureau to Seek Funding for “Income Security System” for Antimicrobials for FY2023
August 29, 2022
- MHLW’s Health Policy Bureau to Seek Budget for Research into Integrating Drug Supply Info, Clarification of Generic Ratio
August 29, 2022
- MHLW Begins Discussions on Potential Use of Non-Doctor/Nurse Healthcare Professionals as Vaccinators
August 29, 2022
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…